Aratana Therapeutics (PETX) Misses Q1 EPS by 10c

Aratana Therapeutics (NASDAQ: PETX) reported Q1 EPS of ($0.52), $0.10 worse than the analyst estimate of ($0.42). Revenue for the quarter came in at $172 thousand versus the consensus estimate of $140 thousand.

For earnings history and earnings-related data on Aratana Therapeutics (PETX) click here.

You May Also Be Interested In

• Home Depot beats estimates, reaffirms fiscal 2026 guidance
• RBC Capital Reiterates Outperform Rating on Lyft (LYFT), a post-earnings debrief with CFO
• Klarna Group plc (KLAR) Tops Q2 EPS by 6c, Beats on Revenue; Offers FY26 Revenue Guidance